Cedric Pobel - Publications

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 17, 2026

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.

Journal: Molecular cancer therapeutics

Published: June 11, 2025

The next-generation of nectin-4 targeted therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 02, 2025

The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond.

Journal: Therapeutic advances in medical oncology

Published: May 01, 2025

Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: February 15, 2024

Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 20, 2024

Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.

Journal: European urology oncology

Published: July 21, 2023

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 21, 2023

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.

Journal: Cancer discovery

Published: December 23, 2022

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 06, 2022

Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers.

Journal: Cancer treatment and research communications

Published: June 01, 2022

Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer.

Journal: Clinical genitourinary cancer

Published: December 29, 2021